AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Approximately 9.5% (US$15.7 million) of global funding was focused on drug development ... the only factor contributing to the absence of antiviral drugs against dengue, but there can be no ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...

SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") is pleased to announce an update on the development of two projects located on industrial brownfield sites located in Skaneateles, ...

The drugmaker is in the latter stages of development for its RSV vaccine ... Pfizer said in a statement that ReViral has a portfolio of antiviral drugs, including a follow-up RSV candidate ...